Clinical Trials

The Heart Cells Foundation, at Barts Health NHS Trust, is funding the pioneering research and development of a revolutionary and potentially life-saving treatment that uses a patient’s own adult stem cells to repair the heart. Helping those with heart disease, whether they have suffered a heart attack or have developed a weak heart for other reasons.  Planning for Phase 3 of the Trials has now begun, alongside the opening of the Compassionate Treatment Centre.

 

The Trials

REGENERATE-IHD, REGENERATE-AMI, REGENERATE-DCM and BAMI .

Trial 1 – Regenerate IHD, treated patients suffering from heart failure from Ischeamic heart disease. The trial has now finished recruitment and follow-up. We have received extremely positive feedback from patients who have felt a marked improvement in their health and everyday lives. We have analysed the data and it has shown positive results towards patients treated with stem cells. The results have been published in medical literature. Setting up a Compassionate Unit to offer treatment to patients suffering with a similar condition.

Trial 2 – Regenerate AMI, treated patients within 24 hours of suffering a heart attack. Now analysed the data has been published in medical literature.

Trial 3 – Regenerate DCM, treated patients with congenital and inherited heart failure. The results, which we are in the process of publishing in the medical press, have shown a positive benefit for patients treated with stem cells over those treated with a placebo.

Trial 4 – BAMI, the biggest and most ambitious trial to date funded by the European Union as a result of the Heart Cells Foundation trials. Patients were recruited from across the UK and Europe. Similar to the criteria of the Regenerate AMI trial, the BAMI trial was treating patients who had recently suffered a heart attack, injecting stem cells into the heart within a week of the treatment of their heart attack.

 

BAMI – European Update

The World’s Largest Adult Stem Cell Heart Attack Trial

Recruitment has now finished and this study is currently in the follow up phase, monitoring patient progress. Once this is completed all data will be reviewed, analysed and results published.